Overview

Sofosbuvir/velpatasvir/voxilaprevir (Vosevi) 400 mg tablets occupy a distinct regulatory niche: a pangenotypic triple direct-acting-antiviral combination reserved for retreatment after prior DAA failure. For compliance-focused B2B buyers, understanding the approved indication boundaries, GMP expectations and documentation requirements is as important as the clinical profile. This guide reviews the regulatory and quality framework surrounding this retreatment regimen.

How It Works

Vosevi combines three direct-acting antivirals with complementary mechanisms: sofosbuvir inhibits the NS5B RNA polymerase, velpatasvir blocks the NS5A protein, and voxilaprevir inhibits the NS3/4A protease. The triple blockade attacks the hepatitis C virus at three essential steps, which is precisely why the regimen is positioned for patients whose virus persisted after earlier NS5A- or NS3-containing therapy. By layering non-overlapping resistance barriers, the combination reduces the chance that pre-existing viral variants survive treatment.

Indications

Vosevi is indicated for adults with chronic hepatitis C genotypes 1 through 6 who were previously treated with an NS5A inhibitor or an NS3/4A protease inhibitor and did not achieve sustained virologic response. Its use is therefore defined by regulatory retreatment criteria rather than first-line initiation. Buyers should align stock with documented retreatment demand and confirm that local licensing supports this specific indication.

Dosage & Administration

The product is supplied as 400 mg film-coated tablets, 28 tablets per box, taken orally once daily with food for a defined treatment course. Tablets are swallowed whole. Buyers should verify the fixed-dose combination strength and the 28-tablet count, because the regimen is a single fixed triplet and cannot be assembled from separate components.

Storage & Sourcing

Store below 30 °C in the original container, protected from moisture and light. As a Gilead-origin branded DAA, Vosevi requires sourcing through authorized channels with verifiable GMP status and batch documentation. Procurement teams should confirm registration, import licensing and controlled handling where required, since retreatment populations are often highly treatment-experienced and cannot tolerate substandard product.

FAQ

Q: Why is Vosevi positioned for retreatment rather than first-line use? It pairs three non-overlapping antiviral mechanisms, making it suited to viruses that survived earlier NS5A or NS3 inhibitor therapy, which defines its regulatory retreatment label.

Q: What regulatory documents should buyers secure? Confirm local registration, import licensing, GMP certificates and batch traceability through authorized distributors before cross-border distribution.

Q: Does the fixed-dose format affect procurement? Yes. Because it is a single triplet tablet, buyers must source the complete 400 mg combination and cannot substitute separate agents.